"; document.getElementById('premiumMsg').innerHTML = contentStr; document.getElementById('premiumMsg').style.display = "block"; } else if (userSingleSale == "Reguser") { contentStr = "" + userStoriesViewed + " of 10 clicks used this month UPGRADE your account for full access to Recordnet.com"; document.getElementById('premiumMsg').innerHTML = contentStr; document.getElementById('premiumMsg').style.display = "block"; } else if (userSingleSale == "PREMIUM01") { document.getElementById('premiumMsg').style.display = "none"; }
July 22, 2013 12:00 AM
LINDEN - After five years as head baseball coach at Linden High, Joe Piombo is moving on.
Piombo has taken a newly created position at McNair High as an on-campus suspension instructor, meaning he'll work with students facing short-term disciplinary action. Rather than serving the traditional at-home suspension, students will report to Piombo's class for the length of their suspensions.
"It's a career move," Piombo said. "I was looking for a different challenge. It's hard to walk away from Linden. I had to remove the emotional part and look at it as a career move for me and my family.
"I think the hardest part is the kids. Our kids start playing for us in the eighth grade. To make that decision now was hard. You look at kids like (Justin) Giovannoni and (Bailey) Wright, we've probably played 100 to 150 games together. It's not an easy decision."
The move has nothing to do with athletics. Quincey Noble, who's been the head baseball coach at McNair since the varsity program's inception in 2007, isn't going anywhere. Piombo said he'll likely help Noble as an assistant.
Piombo, a 1979 Stagg High graduate, has worked as a football coach and baseball coach at Linden off and on since 1989. He took over as head varsity baseball coach in 2009, replacing Bob Amerman, a Stockton Athletic Hall of Famer who won more than 600 games over 43 years.
Piombo's teams went 91-31-2 and won three of the past four Mother Lode League championships. This spring, the Lions went a perfect 15-0 in the MLL (24-6-1 overall), and were one out away from advancing to the Sac-Joaquin Section Division V finals before suffering a 5-3 loss to Escalon in the final game of a best-of-three series.
Contact reporter Stephen Roberson at (209) 546-8272 or sroberson@recordnet.com.
We reserve the right to remove any content at any time from this Community, including without limitation if it violates the Community Rules. We ask that you report content that you in good faith believe violates the above rules by clicking the Flag link next to the offending comment or fill out this form. New comments are only accepted for two weeks from the date of publication.
SAN FRANCISCO (AP) ? Netflix's second-quarter earnings more than quadrupled as the revival of the comedy series "Arrested Development" attracted more subscribers.
Despite the financial gains, the report released Monday flopped on Wall Street because the return of new "Arrested Development" episodes after a seven-year absence didn't add as many U.S. subscribers as many investors had been hoping. Netflix's high-flying stock sank $20.96, or 8 percent, to $241 in extended trading after the numbers came out.
Netflix picked up about 630,000 U.S. subscribers during the three months ending in June. That performance was slightly above the mid-range target set by Netflix Inc.'s management in April. The Los Gatos, Calif., company had predicted it might end the period with as many as 880,000 more subscribers ? a goal that many investors evidently were hoping would be reached.
Expectations had been raised by the Memorial Day weekend release of 15 new "Arrested Development" episodes. The comedy starring Jason Bateman and Michael Cera had built a cult following before its cancellation by the Fox network in 2006 after three seasons.
In a letter to shareholders, Netflix CEO Reed Hastings credited "Arrested Development" for providing a "small but noticeable bump" in subscribers. He praised the company for being able to add more subscribers during the first half of this year than it did last year, despite intensifying competition from other Internet video services run by Amazon.com Inc. and Hulu.
Netflix has added 2.7 million subscribers so far this year, up from 2.5 million at the same time last year.
Hastings was scheduled to elaborate on his views about the past quarter and the rest of the year beginning at 6 p.m. EDT in an unusual talk-show format that will be streamed live over the Internet.
The second-quarter gains leave Netflix with 29.8 million U.S. subscribers to an $8 monthly service that streams video to Internet-connected devices.
Netflix also added 605,000 international subscribers in the second quarter to boost its total customers outside the U.S to 7.75 million.
The company's DVD-by-mail rental service continued a gradual demise as more people embrace the convenience of Internet streaming instead of waiting for discs to be delivered. Netflix lost another 475,000 DVD subscribers in the second quarter, leaving the company with 7.5 million on that side of its service. Netflix has been pushing people toward streaming anyhow because the company believes DVDs are destined for obsolescence and doesn't want to spend a lot on the business any longer.
Netflix earned $29.5 million, or 49 cents per share, in the quarter, up from $6.2 million, or 11 cents per share, a year earlier.
Analysts surveyed by FactSet had forecast earnings of 40 cents per share.
Netflix's revenue climbed 20 percent from last year to $1.07 billion, mirroring analyst projections.
In the current quarter ending in September, Netflix predicted it will add 690,000 to 1.49 million U.S. subscribers.
An Indian court on Saturday handed down life sentences against the six men accused of gang-raping a Swiss tourist on March 16 in central India, local media said.
Those accused of taking part in the rape, between ages 20-30, were convicted by a court in Datia in the state of Madhya Pradesh, with the sentence announced by the court's judge, Kumar Sharma.
The prosecutor who took part in the trial, Rajendra Tiwari, said he was "satisfied" with the life sentences, the maximum penalty for sex crimes according to a law passed in March by the Indian Parliament.
The judge imposed the maximum penalty on the six convicts even though they were not submitted to a police lineup, since the rape took place at night and the woman did not see the faces of her assailants.
The Swiss tourist, 39, was bicycling around India with her husband when they were attacked by several men one night as they were camping. The men gave the husband a beating and raped the woman.
The incident had a particular impact in the media since attacks on foreigners are unusual in the Asian giant.
The sexual abuse of the Swiss tourist is added to the many cases of rape that have been reported in the Indian press since December, when a young 23-year-old woman died after being gang-raped and tortured on a bus in New Delhi.
That crime sparked an unprecedented debate about the condition of women in the Asian country and led Parliament to pass a law in March that toughened sentences for sexual aggressors.
The verdicts against the minor and four of the five adults implicated in the December rape case are expected to be announced at the end of July.
A fifth adult who was among the accused committed suicide in prison last March, authorities said. EFE
Source: webdev.credittrends.moodys.com --- Friday, July 19, 2013 After soaring from May 10's record low 4.99% to June 25's 6.93%, the composite speculative-grade bond yield subsequently eased to July 18's 5.89%. ...
Alternative target for breast cancer drugsPublic release date: 19-Jul-2013 [ | E-mail | Share ]
Contact: Barry Whyte communications@embo.org 49-622-188-91108 European Molecular Biology Organization
HEIDELBERG, 19 July 2013 Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today in EMBO Molecular Medicine, show that elevated levels of the protein Ret, which is short for "Rearranged during transfection", are associated with a lower likelihood of survival for breast cancer patients in the years following surgery to remove tumours and cancerous tissue.
"Our findings suggest that Ret kinase might be an attractive and novel alternative therapeutic target in selected groups of breast cancer patients," remarked Nancy Hynes, Professor at the Friedrich Miescher Institute for Biomedical Re-search and the University of Basel, Switzerland. "Initial experiments in mice that serve as model organisms for the study of breast cancer have revealed that specific inhibitors significantly block the spread of cancer and decrease the number of metastatic tumours found in the lungs."
The scientists examined tumour tissue microarrays of more than 100 breast cancer patients who had undergone surgery to remove their tumours. Antibodies were used to detect the levels of Ret in the samples. In other experiments, four different cancer cell lines were used and injected into mice to study the effects of Ret inhibitors on the progress and spread of the cancer.
"Our findings demonstrate that blocking Ret kinase not only decreases the growth of tumours but also impacts the potential of the cancer to spread throughout the body," Hynes said.
Targeting receptor tyrosine kinase enzymes with antibodies or small molecular inhibitors is a clinically validated approach for cancer therapy. However, only a subset of patients are eligible for these types of treatments which makes it essential to discover additional inhibitors that could be useful in breast cancer therapy.
###
Dr. Albana Gattelli was supported by grant KG101234 from Susan G. Komen for the Cure
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells
Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C. Roloff, Martin Schreiber, Neil Carragher, Kenneth K. Macleod, Michaela Schlederer, Susanne Lienhard, Lukas Kenner, Maria I. Torres-Arzayus and Nancy E. Hynes
Read the paper:
http://onlinelibrary.wiley.com/doi/10.1002/emmm.201302625/abstract
doi: 10.1002/emmm.201302625
Further information on EMBO Molecular Medicine is available at http://www.embomolmed.org
Media Contacts
Barry Whyte
Head | Public Relations and Communications
barry.whyte@embo.org
EMBO is an organization of more than 1500 leading researchers that promotes excellence in the life sciences. The major goals of the organization are to support talented researchers at all stages of their careers, stimulate the exchange of scientific information, and help build a European research environment where scientists can achieve their best work.
EMBO helps young scientists to advance their research, promote their interna-tional reputations and ensure their mobility. Courses, workshops, conferences and scientific journals disseminate the latest research and offer training in techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe.
For more information: http://www.embo.org
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Alternative target for breast cancer drugsPublic release date: 19-Jul-2013 [ | E-mail | Share ]
Contact: Barry Whyte communications@embo.org 49-622-188-91108 European Molecular Biology Organization
HEIDELBERG, 19 July 2013 Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today in EMBO Molecular Medicine, show that elevated levels of the protein Ret, which is short for "Rearranged during transfection", are associated with a lower likelihood of survival for breast cancer patients in the years following surgery to remove tumours and cancerous tissue.
"Our findings suggest that Ret kinase might be an attractive and novel alternative therapeutic target in selected groups of breast cancer patients," remarked Nancy Hynes, Professor at the Friedrich Miescher Institute for Biomedical Re-search and the University of Basel, Switzerland. "Initial experiments in mice that serve as model organisms for the study of breast cancer have revealed that specific inhibitors significantly block the spread of cancer and decrease the number of metastatic tumours found in the lungs."
The scientists examined tumour tissue microarrays of more than 100 breast cancer patients who had undergone surgery to remove their tumours. Antibodies were used to detect the levels of Ret in the samples. In other experiments, four different cancer cell lines were used and injected into mice to study the effects of Ret inhibitors on the progress and spread of the cancer.
"Our findings demonstrate that blocking Ret kinase not only decreases the growth of tumours but also impacts the potential of the cancer to spread throughout the body," Hynes said.
Targeting receptor tyrosine kinase enzymes with antibodies or small molecular inhibitors is a clinically validated approach for cancer therapy. However, only a subset of patients are eligible for these types of treatments which makes it essential to discover additional inhibitors that could be useful in breast cancer therapy.
###
Dr. Albana Gattelli was supported by grant KG101234 from Susan G. Komen for the Cure
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells
Albana Gattelli, Ivan Nalvarte, Anne Boulay, Tim C. Roloff, Martin Schreiber, Neil Carragher, Kenneth K. Macleod, Michaela Schlederer, Susanne Lienhard, Lukas Kenner, Maria I. Torres-Arzayus and Nancy E. Hynes
Read the paper:
http://onlinelibrary.wiley.com/doi/10.1002/emmm.201302625/abstract
doi: 10.1002/emmm.201302625
Further information on EMBO Molecular Medicine is available at http://www.embomolmed.org
Media Contacts
Barry Whyte
Head | Public Relations and Communications
barry.whyte@embo.org
EMBO is an organization of more than 1500 leading researchers that promotes excellence in the life sciences. The major goals of the organization are to support talented researchers at all stages of their careers, stimulate the exchange of scientific information, and help build a European research environment where scientists can achieve their best work.
EMBO helps young scientists to advance their research, promote their interna-tional reputations and ensure their mobility. Courses, workshops, conferences and scientific journals disseminate the latest research and offer training in techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe.
For more information: http://www.embo.org
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Far left outraged ...![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_t7q6YmoA4CQ3B1ie5ziXHWzCOPYH4HDv6YyOgSl-E-4_06ruiSRbaOXEvbU4ohxJrvYORmdmpCqe0GwRhRDsg_vNAa-qQaCgqG43rbQ6Q=s0-d){kind=small}
Public release date: 19-Jul-2013
Share ]